Apr 14, 2020
Carl Gordon named to 2020 Forbes Midas List of top venture capitalistsFeb 3, 2020
OrbiMed Announces New General PartnerJan 16, 2020
OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. MergerJun 18, 2019
OrbiMed Comments on Takeda Pharmaceuticals ProxyApr 2, 2019
Carl Gordon named to 2019 Forbes Midas ListFeb 14, 2019
Passage Bio Founded With $116 million financing, led by OrbiMedDec 11, 2018
OrbiMed's Nash TernsJun 18, 2018
China's Market is a "Once-in-a-Lifetime Opportunity"May 9, 2018
OrbiMed Announces New General PartnerApr 27, 2018
OrbiMed Announces Completion of Leadership TransitionApr 3, 2018
Carl Gordon named to 2018 Forbes Midas ListApr 3, 2018
Jonathan Silverstein named to 2018 Forbes Midas ListFeb 26, 2018
OrbiMed Named Among Most Active European Life Sciences InvestorsSep 26, 2017
OrbiMed Invests $42.5mm in ViviMedSep 25, 2017
In a First, Pfizer Spins Out Biotech Firm with $103 Million in FundingSep 5, 2017
OrbiMed Launches $551 Million Asia Private Equity FundFeb 28, 2017
OrbiMed Logs Two Decades of Novel Attacks on CancerFeb 2, 2017
OrbiMed Comments on Immunomedics Proxy ContestSep 19, 2016
OrbiMed Portfolio Companies Adicet Bio and Rhythm Pharma Ranked In Fierce 15Aug 29, 2016
Cancer Upstart CBT closed $9.7M Series A; OrbiMed Lead InvestorMay 23, 2016
OrbiMed doubles down on Israeli biotechs with $307M fundMay 23, 2016
OrbiMed Launches $307 Million Israel Venture Capital FundMar 15, 2016
OrbiMed Advisors Offers 'One-Stop Shop' for Health-Care CompaniesDec 21, 2015
OrbiMed Launches $950 Million Venture Capital FundDec 17, 2015
The Year's Best VC Deal Was for a Company You've Never Heard OfApr 29, 2015
Betting on China for new Drug Dev BrandVoiceFeb 2, 2015
OrbiMed Launches $924 Million Royalty Credit Opportunities FundSep 9, 2014
OrbiMed Advisors Raises $325M for Second Asia Health-Care Fund